Meropenem

Hypersensitivity to meropenem or other carbapenems. History of severe hypersensitivity reaction (e.g. anaphylactic reaction) to β-lactam antibiotics (e.g. penicillins, cephalosporins).

Patient with CNS disorder (e.g. history of seizure, brain lesions) or condition that may lower seizure threshold (e.g. bacterial meningitis). Renal and hepatic impairment. Neonates and children. Pregnancy and lactation. Monitoring Parameters Perform culture and sensitivity tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor LFT, renal function, and CBC periodically during prolonged treatment. Monitor for signs of anaphylaxis during initiation of treatment.

Significant: CNS effects (e.g. seizure, delirium), fungal or bacterial superinfection (prolonged use), severe cutaneous reactions (e.g. acute generalised exanthematous pustulosis [AGEP], erythema multiforme, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], drug reaction with eosinophilia and systemic symptoms [DRESS]). Blood and lymphatic system disorders: Thrombocythaemia. Gastrointestinal disorders: Nausea, diarrhoea, vomiting, abdominal pain. General disorders and administration site conditions: Inj site inflammation, pain, and thrombophlebitis. Investigations: Increased transaminases, blood alkaline phosphatase, and blood LDH. Nervous system disorders: Headache, paraesthesia. Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Serious hypersensitivity reactions (e.g. anaphylaxis), Clostridioides difficile-associated diarrhoea and pseudomembranous colitis.

May decrease the serum concentrations of valproic acid to subtherapeutic levels, thereby increasing the risk of breakthrough seizures. Increased serum concentration and prolonged elimination half-life with probenecid. May enhance the anticoagulant effects of warfarin.

Other Beta-Lactams

J01DH02 - meropenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.